Cannabis and Pscyhosis
By Ariel Lefland
People have used cannabis, or marijuana, for thousands of years. Now, cannabis is the most widely used of all illicit drugs. Subjective experience from use of the drug ranges from relaxation and mood alteration to hallucination, and paranoia. These reactions are caused by changes in the brain as a result of cannabis’ active ingredient, delta-9-tetrahydrocannabinol (THC), acting on receptors in areas such as the substantia nigra, hippocampus, cerebella cortex and cerebral cortex. There are several known effects of cannabinoid use such as harmful addiction and respiratory disease. However, research is now being conducted to determine if cannabis is linked to another harmful disease—psychosis.
The Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition defines psychosis as a disorder mostly characterized by delusions and hallucinations. A well-known form of psychosis is schizophrenia. The disorder, which literally means, “split mind” is a severe psychopathology characterized by emotional withdrawal, disturbances of thought, hallucinations and delusions. Approximately 1% to 2% of the United States population, or 2.2 million people, is estimated to suffer from the disorder. Geneticists have determined that schizophrenia has a heritable component; concordance rate between monozygotic twins is 48%. It is, therefore, important to understand the relationship between the use of cannabis and the occurrence of psychotic disorders such as schizophrenia.
Studies have clearly indicated a correlation between and the occurrence of psychosis and use of cannabis. Researchers, however, disagree on whether cannabis leads to the onset of psychosis or if psychotic symptoms precipitate cannabis use. Patients who self-medicate psychosis with cannabis provide one gray area for investigators. Furthermore, researchers are still unsure of whether “skunk” and other potent forms of the drug contribute to a higher risk for developing psychosis later in life. For studies that rely on self reported data, confounding variables come into play, clouding results. Thus, research to date remains somewhat inconsistent. Correlation does not show causation, warranting further study to determine the precise relationship between psychosis, especially schizophrenic-like behavior and symptoms, and the use of cannabinoid. This paper will review the current information on this relationship and the ways in which society is interpreting the implications of the scientific data. Although research has not yet produced definitive results, most studies thus far have shown increased risk for schizophrenia in cannabis users when compared with infrequent users or non-users of the drug, especially for individuals with a predisposition for the disorder.
A 2007 review study collected data from 4,804 longitudinal and population based studies. Investigators examined suicidal thoughts, anxiety, and affective disorders, such as depression, separately. Although results of the review suggested an increase risk of any psychotic disorder in individuals who used cannabis more frequently, there were less consistent findings. Non-causal explanations were not fully addressed. There was a substantial confounding effect for both psychotic and affective outcomes.7
A separate review study conducted by Denghardt and Hall aimed to look at vulnerable individuals’ risk in particular. Through an examination of longitudinal studies with a population sample of adolescents and young adults, potential confounders such as other drug use, and personal characteristics were controlled. Biological plausibility was also examined. The results from six studies conducted in five different countries suggested more conclusive results. Researchers found that cannabis use predicts an increased risk of schizophrenia diagnosis or of reporting symptoms of psychosis. Additionally, results seemed to not be a result of cannabis use to self-medicate previously existing symptoms of psychosis. Increased risk was more likely to be a result of personal or family history of schizophrenia.
BBC recently commented on a December 2010 report that suggests using cannabis as a teenager or a young adult increases the risk of psychosis. Published in the British Medical Journal (BMJ), the ten year study was conducted in Germany and tracked 1,923 people from the general population who were between 14 and 24 years of age at the baseline. To determine the causal relationship between psychotic disorders and cannabinoid use, researchers performed a prospective population based cohort study. Investigators followed-up with participants at several points during the ten year time period, including 3.5 years after the start of study (T2) and 8.4 years after the baseline reports (T3). For participants with no lifetime psychotic symptoms and no reported lifetime use of cannabis at the baseline, incidence of cannabis use over the period from baseline to T2 increased the risk of developing psychotic symptoms later observed from T2 to T3. Results also suggest that continued use of cannabis can increase the risk of persistent psychotic symptoms over the period from T2 to T3. By impacting on the persistence of symptoms reminiscent of psychotic disorders, cannabis use may be a dangerous risk factor for the development of incident psychotic symptoms.4
There are important implications that must be taken into consideration as a result of these studies. One possible way to battle this problem is to prevent adolescents from using the drug. A modeling study estimated that between 2,018 and 4,530 young people need prevention from regularly using the drug in the United Kingdom to prevent any cases of schizophrenia. For those who use the drug less frequently, the estimate is four to five times greater; 10,000 to 23,000 individuals must be prevented from taking the drug. A second way in which people can take results of these studies and apply them is through education.
Adolescent use of cannabis is associated with poor education outcomes, increased use of other illicit drugs, increased risk of depression and poor social relationships in early adulthood. If young people and adolescents are educated on the risks of illicit drugs, especially cannabis, the prevalence of psychosis that is related to cannabis use may be decreased. It is questionable whether or not government policy and classification of cannabis has a positive effect on decreasing cannabis use.4 It is interesting to note that about four years ago in July 2007, the British government considered reversing their policy on cannabis. Cannabis had been downgraded from a class B drug to a class C drug. “Weak” evidence on cannabis’ causal relationship to psychosis convinced many that the government need not reverse the decision.6
Hall and Denghardt further explored the implications of scientific findings on the reuse of cannabis as a contributing cause of the onset of psychosis. They compared analyses of similar evidence for the harmful effects of other addictive substances such as alcohol, tobacco, and amphetamine. Researchers concluded that evidence for the causal relationship between cannabis use and psychotic symptoms was as strong as evidence for heavy alcohol use and amphetamine use and psychosis in young adults. Researchers concluded similarly; cannabis use should be discouraged in adolescents and young adults. People must be informed of the potentially hazardous consequences of cannabis use. Caution must be used when considering more lenient legal policies. 7
Subject: Biomedical Science, Public Health
blog comments powered by Disqus